Reduction of inflammatory reaction in the use of purified alginate microcapsules

Journal of Biomaterials Science, Polymer Edition

Volumn 24, Issue 9, 2013, Pages 1084-1098

  Kim, A Ram ^a   Hwang, Ji Hye ^a   Kim, Hye Min ^a   Kim, Ha Neul ^a   Song, Jeong Eun ^a   Yang, Young Il ^b   Yoon, Kun Ho ^c   Lee, Dongwon ^a   Khang, Gilson ^a  

^a Chonbuk National University   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

alginate; biocompatibility; inflammatory reaction; microcapsule; purification

Indexed keywords

ALGINATE MICROCAPSULES; BIOMATERIAL APPLICATION; CONTAMINATED MATERIALS; HISTOLOGICAL EVALUATION; INFLAMMATORY REACTION; MICROCAPSULES; PURIFICATION PROCESS; RAW 264.7 MACROPHAGES;

BIOCOMPATIBILITY; CELL CULTURE; CELL PROLIFERATION; CELLS; ENCAPSULATION; PURIFICATION; TISSUE;

ALGINATE;

ALGINIC ACID; MESSENGER RNA; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CELL ENCAPSULATION; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; GENE EXPRESSION; HISTOLOGY; HYDROPHOBICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MICROCAPSULE; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALGINATES; ANIMALS; CAPSULES; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; DRUG IMPLANTS; DRUG TOXICITY; FEMALE; GLUCURONIC ACID; HEXURONIC ACIDS; INFLAMMATION; MATERIALS TESTING; MICE; NIH 3T3 CELLS; RATS; RATS, WISTAR;

RATTUS;

EID: 84878338631     PISSN: 09205063     EISSN: 15685624     Source Type: Journal    
DOI: 10.1080/09205063.2012.735100     Document Type: Article

References (58)

1. Caliaria, SR, Ramirezb, MA, and, Harley, BAC. 2011. The development of collagen-GAG scaffold-membrane composites for tendon tissue engineering. Biomaterials, 32: 8990-8998.
2. Seal, BL, Otero, TC, and, Panitch, A. 2001. Polymeric biomaterials for tissue and organ regeneration. Mater. Sci. Eng, 34: 147-230.
3. Babensee, JE, McIntire, LV, and, Mikos, AG. 2000. Growth factor delivery for tissue engineering. Pharm. Res, 17: 497-504. (Pubitemid 30416385)
4. Rose, FR, and, Oreffo, RO. 2002. Bone tissue engineering: hope vs hype. Biochem. Biophys. Res. Commun, 292: 1-7. (Pubitemid 34687320)
5. Lee, JH, Park, SJ, Chun, HJ, and, Kim, CH. 2010. Differentiation regulation by microenvironmental interaction control between stem cell and extracelluar matrix. Int. J. Tissue Reg, 1: 1-9.
6. Thomas, A, Harding, KG, and, Moore, K. 2000. Alginates from wound dressings activate human macrophages to secrete tumour necrosis factor-alpha. Biomaterials, 21: 1797-1802. (Pubitemid 30365043)
7. Vacanti, JP, and, Langer, R. 1999. Tissue engineering: The design and fabrication of living replacement devices for surgical reconstruction and transplantation. Lancet, 354: 32-34.
8. Orive1 G, Hernandez1 RM, Gascon AR, Chang TMS, Vos PD, Hortelano G, Hunkeler D, Lacik I, Shapiro AMJ, Pedraz JL. Cell encapsulation: promise and progress. Nat. Med. 2003;9:104-107. (Pubitemid 36098269)
9. Hennink, WE, and, Nostrum, CFV. 2002. Novel crosslinking methods to design hydrogels. Adv. Drug Delivery Rev, 54: 13-36. (Pubitemid 34075312)
10. Kopecek, J. 2007. Hydrogel biomaterials: a smart future?. Biomaterials, 28: 5185-5192. (Pubitemid 47488492)
11. Wang, B, Zhu, W, Zhang, Y, Yang, Z, and, Ding, J. 2006. Synthesis of a chemically-crosslinked thermo-sensitive hydrogel film and in situ encapsulation of model protein drugs. React. Funct. Polym, 66: 509-518.
12. Pitarresi, G, Saiano, F, Cavallaro, G, Mandracchia, D, and, Palumbo, FS. 2007. A new biodegradable and biocompatible hydrogel with polyaminoacid structure. Int. J. Pharm, 33: 130-137. (Pubitemid 46482872)
13. Lim, F, and, Sun, AM. 1980. Microencapsulated islets as bioartificial endocrine pancreas. Science, 210: 908-910. (Pubitemid 11169847)
14. Zielinski, BA, and, Aebischer, P. 1994. Chitosan as a matrix for mammalian cell encapsulation. Biomaterials, 15: 1049-1056. (Pubitemid 24345931)
15. Iwata, H, Amemiya, H, Matsuda, T, Takano, H, Hayashi, R, and, Akutsu, T. 1989. Evaluation of microencapsulated islets in agarose gel as bioartificial pancreas by studies of hormone secretion in culture and by xenotransplantation. Diabetes, 38: 224-225. (Pubitemid 19029286)
16. Dawson, RM, Broughton, RL, Stevenson, WT, and, Sefton, MV. 1987. Microencapsulation of CHO cells in a hydroxyethyl methacrylate-methyl methacrylate copolymer. Biomaterials, 8: 360-366.
17. Kessler, L, Pinget, M, Aprahamian, M, Dejardin, P, and, Damqe, C. 1991. In vitro and in vivo studies of the properties of an artificial membrane for pancreatic islet encapsulation. Horm. Metab. Res, 23: 312-317.
18. Cruise, GM, Hegre, OD, Lamberti, FV, Harger, SR, Hill, R, Scharp, DS, and, Hubbell, JA. 1999. In vitro and in vivo performance of porcine islets encapsulated in interfacially photopolymerized poly(ethylene glycol) diacrylate membranes. Cell Transplant, 8: 293-306. (Pubitemid 29350225)
19. Remminghorst, U, and, Rehm, BH. 2006. Bacterial alginates: from biosynthesis to applications. Biotechnol. Lett, 28: 1701-1712. (Pubitemid 44454893)
20. Iwamoto, Y, Araki, R, Iriyama, K, Oda, T, Fukuda, H, Hayashida, S, and, Muramatsu, T. 2001. Purification and characterization of bifunctional alginate lyase from Alteromonas sp. strain no. 272 and its action on saturated oligomeric substrates. Biosci. Biotechnol. Biochem, 65: 133-142. (Pubitemid 33617451)
21. Uhrich, KE, Cannizzaro, SM, Langer, RS, and, Shakesheff, KM. 1999. Polymeric systems for controlled drug release. Chem. Rev, 99: 3181-3198. (Pubitemid 129583051)
22. Jeong, B, Bae, YH, Lee, DS, and, Kim, SW. 1997. Biodegradable block copolymers as injectable drug-delivery systems. Nature, 388: 860-862. (Pubitemid 27377054)
23. Liew, CV, Chan, LW, Ching, AL, and, Heng, PWW. 2006. Evaluation of sodium alginate as drug release modifier in matrix tablets. Int. J. Pharm, 309: 25-37. (Pubitemid 43129461)
24. Shilpa, A, Agrawal, SS, and, Ray, AR. 2003. Controlled delivery of drugs from alginate matrix. Macromol. Sci. J. Polym. Rev, 43: 187-221.
25. Gombotz, WR, and, Wee, SF. 1998. Protein release from alginate matrices. Adv. Drug Delivery Rev, 31: 267-285. (Pubitemid 28191869)
26. Gaserod, O, Sannes, A, and, Skjak-Brake, G. 1999. Microcapsules of alginate-chitosan. II. A study of capsule stability and permeability. Biomaterials, 20: 773-783. (Pubitemid 29176706)
27. Otterlei, M, Ostgaard, K, Skjaek-Braek, G, Smidsrod, O, Soon-Shiong, P, and, Espevik, T. 1991. Induction of cytokine production from human monocytes stimulated with alginate. Eur. J. Immunol, 10: 286-291.
28. Soon-Shiong, P, Otterlei, M, Skjak-Braek, G, Smidsrod, O, Heintz, R, Lanza, RP, and, Espevik, T. 1991. An immunologic basis for the fibrotic reaction to implanted microcapsules. Transplantation Proc, 23: 758-759.
29. Espevik, T, Otterlei, M, Skjak-Braek, G, Ryan, L, Wright, SD, and, Sundan, A. 1993. The involvement of CD14 in stimulation of cytokine production by uronic acid polymers. Eur. J. Immunol, 23: 255-261. (Pubitemid 23031925)
30. Kim, OY, Kim, SJ, Song, YS, Jo, EH, Hwang, JH, Bae, JY, Yoo, IS, Lee, D, Yun, KH, and, Khang, G. 2011. Purification and characterization of alginate for the application of regenerative medicine. Int. J. Tissue Regen, 2: 13-20.
31. Kim, TH, Ko, JH, Sung, JK, Kim, SJ, and, Park, YH. 2011. Implantable medical textiles. Int. J. Tissue Reg, 2: 1-12.
32. Aaron, GM, and, Gregory, SK. 2009. Alginate modification improves long-term survival and function of transplanted encapsulated islets. Tissue Eng. Part A, 15: 1301-1309.
33. Park, H, Kim, SJ, Kim, S, Song, Y, Seung, K, Hong, D, Khang, G, and, Lee, D. 2010. Antioxidant and anti-inflammatory activities of hydroxybenzyl alcohol releasing biodegradable polyoxalate nanoparticles. Biomacromolecules, 11: 2103-2108.
34. Otterlei, M, Sundan, A, Skjak-Braek, G, Ryan, L, and, Espevik, T. 1993. Similar mechanisms of action of defined polysaccharides and lipopolysaccharides: characterization of binding and tumor necrosis factor alpha induction. Infect. Immun, 61: 1917-1925. (Pubitemid 23145894)
35. Klock, G, Frank, H, Houben, R, Zekorn, T, Horcher, A, Siebers, U, Wohrle, M, Federlin, K, and, Zimmermann, U. 1994. Production of purified alginates suitable for use in immunoisolated transplantation. Appl. Microbiol. Biotechnol, 40: 638-643. (Pubitemid 24048821)
36. Wandrey, C, and, Vidal, DS. 2001. Purification of polymeric biomaterials. Ann. N.Y. Acad. Sci, 944: 187-198. (Pubitemid 34053306)
37. Jork, A, Thurmer, F, Cramer, H, Zimmermann, G, Gessner, P, Hamel, K, Hofmann, G, Kuttler, B, Hahn, HJ, Josimovic-Alasevic, O, Fritsch, KG, and, Zimmermann, U. 2000. Biocompatible alginate from freshly collected Laminaria pallida for implantation. Appl. Microbiol. Biotechnol, 2: 224-229. (Pubitemid 30120576)
38. Prokop, A, and, Wang, T. 1997. Purification of polymers used for fabrication of an immunoisolation barrier. Ann. N.Y. Acad. Sci, 831: 223-231. (Pubitemid 28045277)
39. Khattak, SF, Spatara, M, Roberts, L, and, Roberts, SC. 2006. Application of colorimetric assays to assess viability, growth and metabolism of hydrogel-encapsulated cells. Biotechnol. Lett, 28: 1361-1370.
40. Pegues, AS, Sofer, SS, McCallum, RE, and, Hinshaw, LB. 1979. The removal of 14C labeled endotoxin by activated charcoal. Int. J. Artif. Organs, 2: 153-158. (Pubitemid 9253431)
41. Nolan, JP, McDevitt, JJ, Goldmann, GS, and, Bishop, C. 1975. Endotoxin binding by charged and uncharged resins. Proc. Soc. Exp. Biol. Med, 149: 766-770.
42. Arimori, K, and, Nakano, M. 1989. Study on transport of disopyramide into the intestinal lumen aimed at gastrointestinal dialysis by activated charcoal in rats. J. Pharm. Pharmacol, 41: 445-449. (Pubitemid 19189584)
43. Tam SK, Dusseault J, Polizu S, Menard M, Halle JP, Yahia L. Impact of residual contamination on the biofunctional properties of purified alginates used for cell encapsulation. Biomaterials. 2006;27:1296-1305. (Pubitemid 41739554)
44. Cooper, JA, Lu, HH, Ko, FK, Freeman, JW, and, Laurencin, CT. 2005. Fiber-based tissue-engineered scaffold for ligament replacement: design considerations and in vitro evaluation. Biomaterials, 26: 1523-1532. (Pubitemid 39441385)
45. Lim, EJ, Kang, HJ, Jung, HJ, and, Park, EH. 2007. Anti-angiogenic, anti-inflammatory and anti-nociceptive activity of 4-hydroxybenzyl alcohol. J. Pharm. Pharmacol, 59: 1235-1240.
46. Jacobs, AT, and, Ignarro, LJJ. 2001. Lipopolysaccharide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW 264.7 macrophages. J. Biol. Chem, 276: 47950-47957.
47. Lee, HJ, Lim, HJ, Lee, DY, Jung, H, Kim, MR, Moon, DC, Kim, KI, Lee, MS, and, Ryu, JH. 2010. Carabrol suppresses LPS-induced nitric oxide synthase expression by inactivation of p38 and JNK via inhibition of I-kappaBalpha degradation in RAW 264.7 cells. Biochem. Biophys. Res. Commun, 391: 1400-1404.
48. Numata, M, Suzuki, S, Miyazawa, N, Miyashita, A, Nagashima, Y, Inoue, S, Kaneko, T, and, Okubo, T. 1998. Inhibition of inducible nitric oxide synthase prevents LPS-induced acute lung injury in dogs. J. Immunol, 160: 3031-3037. (Pubitemid 28136760)
49. Azad, N, Rojanasakul, Y, and, Vallyathan, V. 2008. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J. Toxicol. Environ. Health Part B, 1: 1-15.
50. Kim, SF, Huri, DA, and, Snyder, SH. 2005. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science, 310: 1966-1970. (Pubitemid 43005992)
51. Takeichi, O, Saito, I, Okamoto, Y, Tsurumachi, T, and, Saito, T. 1998. Cytokine regulation on the synthesis of nitric oxide in vivo by chronically infected human polymorphonuclear leucocytes. Immunology, 93: 275-280. (Pubitemid 28088297)
52. Koarai, A, Ichinose, M, Sugiura, H, Tomaki, M, Watanabe, M, Yamagata, S, Komaki, Y, Shirato, K, and, Hattori, T. 2002. iNOS depletion completely diminishes reactive nitrogen-species formation after an allergic response. Eur. Respir. J, 20: 609-616.
53. Goode, HF, Webster, NR, Howdle, PD, and, Walker, BE. 1994. Beta-adrenoceptor subtypes which mediate the metabolic effects of BRL 35135 in man. Clin. Sci, 86: 411-416.
54. Yan, L, Vandivier, RW, Suffredini, AF, and, Danner, RL. 1994. Human polymorphonuclear leukocytes lack detectable nitric oxide synthase activity. J. Immunol, 153: 1825-1834. (Pubitemid 24251128)
55. Lirk, P, Hoffmann, G, and, Rieder, J. 2002. Inducible nitric oxide synthase-time for reappraisal. Curr. Drug Targets Inflamm. Allergy, 1: 89-108.
56. Martinsen, A, Skjak-Baek, G, and, Smidsrod, O. 1989. Alginate as immobilization material: I. Correlation between chemical and physical properties of alginate gel beads. Biotechnol. Bioeng, 33: 79-89. (Pubitemid 19010127)
57. Yoon, SJ, Kim, SH, Ha, HJ, Ko, YK, So, JW, Kim, MS, Yang, YI, Khang, G, Rhee, JM, and, Lee, HB. 2008. Reduction of inflammatory reaction of poly(d,l-lactic-co-glycolic acid) using demineralized bone particles. Tissue Eng. Part A, 14: 539-547. (Pubitemid 351520462)
58. Soon-Shiong, P, Feldman, E, Nelson, R, Heintz, R, Yao, Q, Yao, Z, Zheng, T, Merideth, N, Skjak-Braek, G, and, Espevik, T. 1993. Long-term reversal of diabetes by the injection of immunoprotected islets. Proc. Natl. Acad. Sci. USA, 90: 5843-5847. (Pubitemid 23176259)